Question normal

TOPIC 1: Is there a chance of confounding on regards to the patient´s length of stay and temporal introduction of valid anti-Covid treatments?
• My question deals with the concern of which anti-thrombotic measures were taken for patients surpassing trial´s therapeutic coagulation time, particularly for those with low mobilization, or still to be bedridden for more than 14 days, and those on which recovery was sooner, and whether there could be an influence on the net effect reported in the non-critical patients’ trial.
• In our experience when we started to be consistent in using Dexamethasone (June 2020, preliminary), Tocilizumab (January 2021), Remdesivir (October 2020) at different months over 2020. We know now that the primary outcome that was studied by your group is influenced by multi-targeted interventions, thereof, which is your estimate that the a posteriori adaptative-randomization that was done might have been influenced by the confounding effects of the time-varied introduction of Dexamethasone, Tocilizumab, and Remdesivir.

TOPIC 2: Which has been the criteria to choose which patients were candidates to high flow nasal cannula (HFNC) use on the centers in your study.
• During our time containing Covid 19 epidemic, we have seen different patterns in choosing when to use HFNC: it has been mostly related to physicians' practice patterns, HFNC availability, patient´s comfort, patients' wishes for more conservative management, etc. Should this figure is mirrored elsewhere, I wonder whether there might be a different size effect in terms of applying therapeutic anticoagulation in our context.